Abstract: Objective: To summarize our experience in treating 36 cases of children's Wilms' tumor with combined therapy in recent years. Methods: A total of 36 patients diagnosed with Wilms'tumor attended the clinic between April1998 and May 2002. The average age was 3.8 years (ranging from 5.5 to 11 years). The patients were classified into Ⅰ~Ⅳstages by clinical situation and identified as favorable histology(FH) and unfavorable histology(UFH) according to National Wilms' Tumor Study Group (NWTSG) and the International Society of Pediatric Oncology (SIOP) criteria. Those patients with FH stage Ⅰ~Ⅱ received surgery combined with low-dose postoperative chemotherapy. Those patients with stage Ⅲ~Ⅳ or UFH were treated with intensive postoperative chemotherapy plus 1080cGy flank/abdominal radiation. Another1080cGy flank radiation was requisite when the residual tumor was larger than 3cm. In children with lung metastases de-tected in chest radiograph, the whole lung irradiation (1200cGy in 8 fractions) should be administered. The 3-year overallsurvival (OS) rate and 3-year disease-free survival (DFS) rate were estimated. Results: The mean period of follow up was55.47 months (ranging from 5 to 108 months). The 3-year OS and 3-year DFS of all patients were 86.11% and 75%, re-spectively. The 3-year OS and 3-year DFS were 100% and 100% in stage I cases, 93.3% and 86.7% in stage Ⅱ patients,88.9% and 77.8% in stage Ⅲ cases, and 60% and 20% in stage Ⅳ patients, respectively. The 3-year OS and 3-year DFS were 94.7% and 89.5% in patients with FH, and 76.5% and 58.8% in patients with UFH, CCSK or RTK. A statistically significant difference was found in the 3-year DFS rate between stage Ⅲ and Ⅳ cases(P=0.031 5), and between FH group and UFH+CCSK+RTK group (P=0.017 5). No therapy-related death and long-term sequelae were observed. Conclusion: The standard combined therapy for patients with Wilms' tumor can achieve good effects and is well tolerated.